Hyperfine (HYPR) Competitors $0.73 +0.01 (+0.69%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$0.73 0.00 (-0.27%) As of 05/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPR vs. PDEX, NVRO, LUNG, NYXH, RCEL, CVRX, ELMD, INGN, AVR, and DRTSShould you be buying Hyperfine stock or one of its competitors? The main competitors of Hyperfine include Pro-Dex (PDEX), Nevro (NVRO), Pulmonx (LUNG), Nyxoah (NYXH), AVITA Medical (RCEL), CVRx (CVRX), Electromed (ELMD), Inogen (INGN), Anteris Technologies Global (AVR), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry. Hyperfine vs. Pro-Dex Nevro Pulmonx Nyxoah AVITA Medical CVRx Electromed Inogen Anteris Technologies Global Alpha Tau Medical Pro-Dex (NASDAQ:PDEX) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Do insiders & institutionals have more ownership in PDEX or HYPR? 15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 47.5% of Pro-Dex shares are held by insiders. Comparatively, 31.0% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, PDEX or HYPR? Pro-Dex has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Do analysts rate PDEX or HYPR? Pro-Dex presently has a consensus target price of $52.00, indicating a potential downside of 22.73%. Hyperfine has a consensus target price of $1.33, indicating a potential upside of 82.19%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than Pro-Dex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer PDEX or HYPR? In the previous week, Pro-Dex had 3 more articles in the media than Hyperfine. MarketBeat recorded 5 mentions for Pro-Dex and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.44 beat Pro-Dex's score of 0.94 indicating that Hyperfine is being referred to more favorably in the news media. Company Overall Sentiment Pro-Dex Positive Hyperfine Positive Is PDEX or HYPR more profitable? Pro-Dex has a net margin of 11.06% compared to Hyperfine's net margin of -309.42%. Pro-Dex's return on equity of 21.68% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets Pro-Dex11.06% 21.68% 12.40% Hyperfine -309.42%-57.54%-50.38% Which has stronger earnings and valuation, PDEX or HYPR? Pro-Dex has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPro-Dex$61.00M3.60$2.13M$2.0133.48Hyperfine$12.89M4.41-$44.24M-$0.56-1.30 Does the MarketBeat Community favor PDEX or HYPR? Pro-Dex received 149 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 61.75% of users gave Pro-Dex an outperform vote while only 50.00% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformPro-DexOutperform Votes15561.75% Underperform Votes9638.25% HyperfineOutperform Votes650.00% Underperform Votes650.00% SummaryPro-Dex beats Hyperfine on 13 of the 18 factors compared between the two stocks. Get Hyperfine News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPR vs. The Competition Export to ExcelMetricHyperfineElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.82M$3.18B$5.53B$7.93BDividend YieldN/A1.80%5.11%4.22%P/E Ratio-1.2815.4222.5118.54Price / Sales4.4155.55397.62103.30Price / CashN/A44.0938.1834.62Price / Book0.623.536.734.25Net Income-$44.24M$94.03M$3.22B$248.18M7 Day Performance-3.57%1.00%1.38%1.03%1 Month Performance-0.68%4.45%2.79%2.70%1 Year Performance-7.93%-18.19%15.41%4.05% Hyperfine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPRHyperfine3.5811 of 5 stars$0.73+0.7%$1.33+82.2%-8.9%$56.82M$12.89M-1.28190Short Interest ↓PDEXPro-Dex1.4247 of 5 stars$69.00+6.3%$52.00-24.6%+261.6%$225.01M$61.00M34.33140Earnings ReportShort Interest ↑News CoverageHigh Trading VolumeNVRONevro0.1892 of 5 stars$5.85+0.1%$5.36-8.3%-43.8%$224.32M$408.52M-3.091,090Upcoming EarningsAnalyst ForecastLUNGPulmonx3.731 of 5 stars$5.19-0.2%$12.75+145.7%-51.2%$208.88M$83.79M-3.60250Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap UpNYXHNyxoah2.2831 of 5 stars$6.01+2.4%$14.50+141.3%-36.6%$204.70M$4.52M-3.21110RCELAVITA Medical1.6879 of 5 stars$10.25+1.8%$17.25+68.3%+8.0%$198.26M$64.25M-4.29130Upcoming EarningsPositive NewsCVRXCVRx3.1145 of 5 stars$7.52+11.7%$16.83+123.8%-28.0%$195.79M$51.29M-2.80160Upcoming EarningsShort Interest ↓News CoveragePositive NewsHigh Trading VolumeELMDElectromed0.6146 of 5 stars$22.87-0.8%$38.00+66.2%+30.6%$195.70M$59.63M30.49160Analyst UpgradeINGNInogen2.5599 of 5 stars$7.27-0.1%$7.00-3.7%+0.1%$195.47M$335.71M-3.231,030Upcoming EarningsShort Interest ↑Positive NewsAVRAnteris Technologies GlobalN/A$5.39+8.2%$16.50+206.1%N/A$194.17M$2.71M0.00138News CoveragePositive NewsHigh Trading VolumeDRTSAlpha Tau Medical2.036 of 5 stars$2.64flat$8.00+203.0%+7.8%$185.81MN/A-6.1480Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Pro-Dex Alternatives Nevro Alternatives Pulmonx Alternatives Nyxoah Alternatives AVITA Medical Alternatives CVRx Alternatives Electromed Alternatives Inogen Alternatives Anteris Technologies Global Alternatives Alpha Tau Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperfine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperfine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.